{
    "ticker": "CKPT",
    "name": "Checkpoint Therapeutics, Inc.",
    "description": "Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of solid tumors and hematologic malignancies. Founded in 2015 and headquartered in New York City, Checkpoint is dedicated to advancing the field of oncology through its robust pipeline of targeted therapies and immuno-oncology agents. The company's lead product candidate, CK-301, is an anti-PD-L1 monoclonal antibody that is currently being evaluated in clinical trials for the treatment of various cancers. Checkpoint is also advancing other promising compounds, including CK-101, a novel selective inhibitor of the epidermal growth factor receptor (EGFR), which is being developed for patients with EGFR-driven tumors. The company's mission is to bring forth new hope for patients battling cancer by addressing unmet medical needs with its innovative therapeutic approaches. Checkpoint is committed to scientific excellence and collaborates with leading research institutions and industry partners to enhance its drug development capabilities. With a focus on precision medicine, Checkpoint Therapeutics aims to provide more effective treatment options and improve the quality of life for cancer patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2015",
    "website": "https://www.checkpointtx.com",
    "ceo": "James A. Oliviero, Jr.",
    "social_media": {
        "twitter": "https://twitter.com/CheckpointTx",
        "linkedin": "https://www.linkedin.com/company/checkpoint-therapeutics/"
    },
    "investor_relations": "https://investors.checkpointtx.com",
    "key_executives": [
        {
            "name": "James A. Oliviero, Jr.",
            "position": "CEO"
        },
        {
            "name": "Michael H. S. Wong",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapeutics",
            "products": [
                "CK-301",
                "CK-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Checkpoint Therapeutics, Inc. | Innovative Cancer Therapies",
        "meta_description": "Explore Checkpoint Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment. Learn about our lead product candidates and mission to fight cancer.",
        "keywords": [
            "Checkpoint Therapeutics",
            "Oncology",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "CK-301",
            "CK-101"
        ]
    },
    "faq": [
        {
            "question": "What is Checkpoint Therapeutics known for?",
            "answer": "Checkpoint Therapeutics is known for developing innovative therapies for cancer treatment, including targeted therapies and immuno-oncology agents."
        },
        {
            "question": "Who is the CEO of Checkpoint Therapeutics?",
            "answer": "James A. Oliviero, Jr. is the CEO of Checkpoint Therapeutics, Inc."
        },
        {
            "question": "Where is Checkpoint Therapeutics headquartered?",
            "answer": "Checkpoint Therapeutics is headquartered in New York City, New York, USA."
        },
        {
            "question": "What are Checkpoint Therapeutics' main products?",
            "answer": "Checkpoint Therapeutics' main product candidates include CK-301 and CK-101."
        },
        {
            "question": "When was Checkpoint Therapeutics founded?",
            "answer": "Checkpoint Therapeutics was founded in 2015."
        }
    ],
    "competitors": [
        "MRNA",
        "BMY",
        "AMGN",
        "REGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "GILD",
        "ABBV"
    ]
}